Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: R. Ramesh who wrote (826)	6/15/1999 1:51:00 PM
From: Anthony Wong	Respond to of 942

The Captain may not agree, but I think $61ish is a good entry point; may not drop that low this time. PFE reversed today. May take a while before you'll see any significant price improvement. Good news yet to come is the announcement of the PFE drug WLA gets to co-promote. Anthony

To: R. Ramesh who wrote (826)	6/15/1999 2:09:00 PM
From: Anthony Wong	Respond to of 942

Magic 25 - Warner Lambert, Along With Drug Stocks, Remain Under Pressure Jun 15, 1999 After several years of strong gains, drug stocks have slid precipitously over the last few months. The AMEX Pharmaceutical Index (AMEX:DRG) has fallen to 350 after hitting 425 in early April. Shares of Warner Lambert have fallen in sympathy, and are now down 27% from the 52-week high of $85.94. That sell-off, though, has created a compelling buying opportunity. Everen's Jeff Kraws concurs, noting that "Merck (NYSE:MRK - news) , Eli Lilly (NYSE:LLY - news) , Pfizer (NYSE:PFE - news) , the distributors and the pharmaceutical sector in general has been taking a hit. But, we think that the number and quality of drugs in the pipelines of some of these companies, Warner Lambert in particular, is very attractive". What will help to drive the stock back up you ask? Wall Street is expecting to hear more about Pfizer's (NYSE:PFE - news) "quid" product. The quid product will go to Warner Lambert in exchange for Pfizer's co-promotion of Lipitor (which treats high levels of cholesterol in patients). The "quid" may be one or several products. Wall Street thinks, however, that the potential of Pfizer's product will be substantial, as Lipitor has been a very successful product for Warner Lambert with first quarter sales of $751 million and 1998 sales of $2.2 billion. Gruntal's David Saks thinks that Lipitor could generate as much as "$4.25 billion in FY 2000." It is the strength of this product that leads us to believe that the quid product will be a real blockbuster. In addition to the above catalyst, Wall Street is very positive on the pipeline product at Warner Lambert. One product, Pregabalin, with indications in epilepsy is expected to be filed with the FDA (for approval) within 18 months. Wall Street thinks that Pregabalin has the potential to be a $1-$2 billion product. Other drugs in the pipeline with indications for depression, diabetes, and arthritis may also help to provide a much needed catalyst in the form of news in coming months. It's also important to note that bad news regarding Rezulin has already been factored into the stock price. There had been some concern that Rezulin, which is used to treat type II diabetes might have been pulled off the shelves due to abnormally high rates of liver toxicity in patients taking the product. This did not happen, but had been a damper on the stock price. Consensus estimates have the company earning $0.51 per share on average for the June quarter. Based upon what we are hearing from the company and from others in the industry, there should be no surprises. For the year Wall Street is expecting the company to earn $1.92 per share and $2.32 per share on average in FY 2000. Shares of Warner Lambert are undervalued based upon near term weakness in the pharmaceutical industry as well as the anticipated earnings growth rate of 20.9%. Analyst: Glenn S. Curtis Updated on 6/15/99 with WLA trading at $62.63 Recommended 11/16/98 at $73.63 fnews.yahoo.com

To: R. Ramesh who wrote (826)	6/16/1999 12:59:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 942

Warner-Lambert Could Market Pfizer's Migraine Drug (Update1) Bloomberg News June 16, 1999, 9:54 a.m. ET Warner-Lambert Could Market Pfizer's Migraine Drug (Update1) (Adds analyst comment in 3rd and 4th paragraphs. Updates share prices.) Morris Plains, New Jersey, June 16 (Bloomberg) -- Warner- Lambert Co., maker of the No. 1 cholesterol pill in the U.S., Lipitor, said it will help market Pfizer Inc.'s migraine drug, Relpax, which could win U.S. and European approvals this year. Warner-Lambert and Pfizer also will try to develop one pill that combines Lipitor with Pfizer's Norvasc, the world's best- selling high-blood-pressure drug. Lipitor and Norvasc already each top $2 billion in annual sales. The combination pill hasn't been tested yet, even in animals, Pfizer said. Warner-Lambert and Pfizer extended their co-promotion agreement for Lipitor for a total of 10 years. As part of the Lipitor pact, Warner-Lambert won the right to market a Pfizer drug. The Norvasc agreement helps make the choice of Relpax more attractive, an analyst said. About 27 million people have both high blood pressure and high cholesterol. ''Relpax is one of the weaker Pfizer pipeline drugs that Warner could have chosen,'' said Alex Zisson, an analyst with Hambrecht & Quist, who has a ''market perform'' rating on both companies. Morris Plains, New Jersey-based Warner-Lambert rose 9/16 to 62 1/4 in early trading. New York-based Pfizer rose 2 3/16 to 99 3/4. Relpax will compete with migraine medicines that Glaxo Wellcome Plc, Merck & Co. and AstraZeneca Plc have introduced in recent years. None of these has threatened Glaxo's older migraine medicine, Imitrex as much as expected or attracted many new patients to seek treatment, Zisson said. ''The second-generation migraine agents didn't expand the market as much as people had hoped,'' Zisson said.